AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00977457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
Study NCT04121845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Sinus Reducer device
Description: Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
Study NCT04121845 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
Study NCT01743833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)
Study NCT01743833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapular High Velocity, Low Amplitude Thrust Maneuver
Study NCT02611401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life.
Study NCT02611401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session.
Study NCT00553462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00553462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00553462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Study NCT00553462 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02958943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-screen electronic alert
Description: On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
Study NCT02698098 — intervention group
Intervention type: DRUG
Intervention: Methadone
Study NCT02796755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.
Study NCT00977457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT02796755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
Study NCT03628027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerised decision support algorithm
Description: The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
Study NCT00778973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline 100 mg tablets
Study NCT00778973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline 100 mg tablets
Study NCT02921061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT02921061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02921061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT02921061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT02921061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02921061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT04218565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL)
Description: Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
Study NCT02166671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV booster vaccination 1dose
Study NCT02012868 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery
Study NCT00430183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
Study NCT00430183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Given intramuscularly
Study NCT00430183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
Study NCT00430183 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
Study NCT03965000 — intervention group
Intervention type: OTHER
Intervention: Mixed-meal-tolerance-test
Description: To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
Study NCT03986073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-F3083 capsule 10 mg
Description: Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
Study NCT03986073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-F3083 capsule 20 mg
Description: Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
Study NCT02023853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erythritol
Study NCT02023853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole gel
Study NCT03752528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Determination of buprenorphine and norbuprenorphine plasma concentrations
Study NCT03986073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-F3083 blank analog capsule
Description: Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
Study NCT03986073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQ-F3083 blank analog capsule
Description: Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
Study NCT03986073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQ-F3083 blank analog capsule
Description: Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
Study NCT03986073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin blank analog tablet
Description: Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
Study NCT03752528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample collection
Description: Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration
Study NCT01437501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout Extract Beverage
Description: Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
Study NCT02856165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal canula oxygen therapy
Description: High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F\&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 > 94%.
Study NCT01437501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo beverage
Description: 100 mL of dilute pineapple and lime juice daily for 84 days.
Study NCT02096718 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib healthy
Study NCT02096718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib severe renally impaired
Study NCT02096718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib moderate renally impaired
Study NCT03834883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Study NCT02856165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow oxygen therapy with standard nasal canula
Description: flow adjusted to SpO2 > 94% (up to a maximum of 2l/min).
Study NCT00675025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride (Aricept)
Description: Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
Study NCT06160401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singletine
Description: Singletine orally administered
Study NCT06160401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered
Study NCT03986073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin blank analog tablet
Description: Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
Study NCT03986073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin tablet
Description: Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
Study NCT03834883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Study NCT03834883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Study NCT03411330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase
Description: Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
Study NCT01845545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early provision of microfinance
Description: The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
Study NCT02487108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46763
Description: TV-46763 will be administered per dose and schedule specified in the arm description.
Study NCT02487108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
Study NCT03889587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Innervation
Description: There will be simultaneous innervation of vascularized iliac or fibular bone flaps through neurorrhaphy between the nerves innervating iliac or fibular bones and recipient site.
Study NCT03889587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-innervation
Description: This will be the traditional method of vascularized iliac or fibular bone flaps, and neurorrhaphy will not be performed.
Study NCT01589484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWL - Compact Delta Dornier Med Tech
Description: All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
Study NCT01880411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEK Fusion Protein Vaccine
Description: PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
Study NCT03411330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
Study NCT03411330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine (0.5%)
Study NCT00311298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multimicronutrients
Description: Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
Study NCT03447860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAACC
Description: Mindfulness based caregiver intervention that includes education , problem solving, skill building, stress management and mindfulness to help enhance compassion and acceptance of self and others
Study NCT03447860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REACH-VA
Description: A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress
Study NCT02030353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation plus activity monitoring
Description: Individual in-person session, digital smart scale, online intervention, and an activity monitor.
Study NCT02030353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation
Description: Individual in-person session, digital smart scale, and online intervention.
Study NCT01327690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT (Cognitive Behavior Therapy)
Description: CBT group therapy sessions
Study NCT01327690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: Group therapy sessions using EFT
Study NCT01423526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP10292
Description: Drug: DWP10292 tablets, oral administration, single administration
Study NCT01423526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, oral administration, single administrations
Study NCT00311298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multimicronutrients
Description: Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
Study NCT00311298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy and proteins
Description: Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
Study NCT00311298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy and proteins
Description: Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
Study NCT02143050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Study NCT02143050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Study NCT02143050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04869748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfetti method
Description: * Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Participants received a 15-minute session of Perfetti method on affected elbow flexor.~* Participants were asked to concentrate on the position of their elbows.~* Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~* After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol.
Study NCT04869748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: passive stretching
Description: * Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes.
Study NCT00574964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gliadel Wafer, Temodar and Radiotherapy
Description: Given concurrently starting 10-30 days after surgery.
Study NCT03635671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography Angiography
Description: Retinal scans will be acquired at each follow up visit
Study NCT00104598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Study NCT00104598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence Program
Description: This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.